Navigation Links
Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy
Date:9/19/2011

enues from sales and service of its products.  Calypso currently has an installed base of more than 110 systems in North America and Europe.  The tracking system has been used in the treatment of an estimated 10,000 patients for cancer of the prostate.  

It is expected that the Calypso business will be integrated into Varian's Oncology Systems segment and will continue to operate in Seattle.  Including transaction and integration costs, Varian anticipates that the Calypso acquisition will be slightly dilutive to earnings per diluted share in fiscal year 2012.  The acquisition includes Calypso's intellectual property portfolio with some 90 current or pending patents.

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

About Calypso Medical Technologies, Inc.
Calypso Medical is a privately held medical device company headquartered in Seattle. Its proprietary   tumor localization system is designed for body-wide cancers commonly treated with radiation. Utilizing miniaturized, non-ionizing implanted d
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
(Date:7/24/2014)... DALLAS , July 24, 2014 /PRNewswire-iReach/ -- ... days once order is placed. Photo ... is a professional and in-depth market survey on ... firstly reviews the basic information of Hemodialysis Machine ... report then explores global and China,s top manufacturers ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... today announced that it has appointed world-renowned clinical genomics ... Scientific Advisory Board.   Dr. Chinnaiyan is ... the clinic to choose appropriate therapies for cancer patients. ...
... SAN DIEGO, Jan. 19, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... Food and Drug Administration (FDA) has established a Prescription Drug ... the review of the Exelbine (ANX-530) New Drug Application (NDA). ... that the application is sufficiently complete to permit a substantive ...
Cached Medicine Technology:WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 2WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 3WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 4ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 2ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 3
(Date:7/24/2014)... Journal of Oral Implantology —Success of a ... the alveolar ridge—an indication of the amount of bone ... exist, each with their own advantages, to determine bone ... highlighted as a strategy for treating horizontally collapsed alveolar ... comparison of two commonly used techniques , the ...
(Date:7/24/2014)... The U.S. Preventive Services Task Force recently ... at high risk for cancer, but a potential ... have positive results on the screening test, only ... policymakers have expressed concern that this high false-positive ... A new study of National Lung Screening Trial ...
(Date:7/24/2014)... Voted one of the most reliable online dress ... on providing its new and old customers with the ... has announced its new collection of high end wedding ... according to the latest fashion trends. Additionally, they are ... , As a matter of fact, high end special ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay News) -- ... according to a small study that asked boys what they really ... the ages of 14 and 16, researchers found that most said ... trust. Very few boasted about sexual conquests or saw sex as ... "In our culture, we have lots of assumptions about how guys ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... called infective endocarditis, coupled with heart failure, heart valve surgery ... new study suggests. Infective endocarditis, an infection of ... valves, has been associated with a high risk of death. ...
... , TUESDAY, Nov. 22 (HealthDay News) -- ,Taking slightly ... the brand name Tylenol) over time can lead to an ... a new study. These "staggered overdoses" can occur when ... acetaminophen than they should, explained Dr. Kenneth Simpson, author of ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... "energy" drinks skyrockets, so do related health problems, a ... almost 10 times more cases of reactions to beverages such ... to a new U.S. government report released Tuesday. More ...
... , TUESDAY, Nov. 22 (HealthDay News) -- Elderly black ... are much more likely to die in the hospital than ... risk of death was present even when black patients had ... researchers found. Diverticulitis occurs when small pouches in the ...
... discovered the novel protective role dendritic cells play in ... issue of journal Gastroenterology , shows dendritic cells ... dangerous swelling and inflammation of the pancreas gland. ... dendritic cells are needed in the pancreas for normal, ...
... News) --,College students tend to smoke when they are partying, ... are using social events and work as cues to remind ... an assistant professor of family and community medicine at the ... "This research is important for those working with college students ...
Cached Medicine News:Health News:Surgery May Boost Survival With Dangerous Heart Condition 2Health News:Surgery May Boost Survival With Dangerous Heart Condition 3Health News:Too Much Acetaminophen Over Time May Damage Liver 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 3Health News:More Blacks Die in Hospital After Diverticulitis Surgery 2Health News:Dendritic cells protect against acute pancreatitis 2Health News:Dendritic cells protect against acute pancreatitis 3Health News:College Students Smoke When They Party, Drink and Work 2
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Custom programming of 3 hot blocks and 1 cold block, 30% reduction in cycling time, Unmatched well-to-well uniformity, No gradient feature...
... With Exceptional Performance The sleek ... might be the first things ... is designed for performance. With ... premium, its small footprint is ...
... The 96-Well GeneAmp PCR System 9700 ... and Aluminum Sample Blocks Modules. The aluminum ... of PCR reactions and cycle sequencing in ... This allows the 96-well 9700 system to ...
Medicine Products: